This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/pubchem-substance/
n21http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n27http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n23http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00529/identifier/chebi/
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00529
rdf:type
n5:Drug
n5:description
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. [PubChem]
n5:dosage
n24:271B3F72-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
3.3-6.8 hours
n5:indication
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
n5:manufacturer
n18:271B3F6E-363D-11E5-9242-09173F13E4C5 n18:271B3F6D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n20:DB00529 n21:DB00529
dcterms:title
Foscarnet
adms:identifier
n4:3297 n7:DB00529 n9:127780 n10:PA449706 n11:3415 n12:D00579 n13:0186-1906-01 n14:Foscarnet n15:46507873
n5:mechanismOfAction
Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases.
n5:packager
n18:271B3F6C-363D-11E5-9242-09173F13E4C5 n18:271B3F6A-363D-11E5-9242-09173F13E4C5 n18:271B3F6B-363D-11E5-9242-09173F13E4C5
n5:synonym
Phosphonomethanoic acid Foscarmet Phosphonoformate Phosphonoformic acid Foscarnet Carboxyphosphonic acid
n5:toxicity
Oral, rat LD<sub>50</sub>: >2,000 mg/kg. Signs of overdose include renal impairment.
n5:proteinBinding
14-17%
n5:salt
n5:synthesisReference
Charles E. McKenna, "Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid." U.S. Patent US5072032, issued February, 1953.
n27:hasConcept
n28:M0026166
foaf:page
n23:foscarnet.htm n26:foscarnet.html
n5:IUPAC-Name
n6:271B3F77-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B3F7D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B3F7C-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B3F79-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B3F7A-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B3F7B-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B3F75-363D-11E5-9242-09173F13E4C5 n6:271B3F8C-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B3F76-363D-11E5-9242-09173F13E4C5 n6:271B3F73-363D-11E5-9242-09173F13E4C5 n6:271B3F8E-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B3F74-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:J05AD01
n5:H-Bond-Acceptor-Count
n6:271B3F83-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B3F84-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B3F7E-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B3F7F-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B3F81-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B3F80-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B3F82-363D-11E5-9242-09173F13E4C5
n5:absorption
Poorly absorbed after oral administration (bioavailability from 12 to 22%).
n5:affectedOrganism
Human Herpes Virus
n5:casRegistryNumber
63585-09-1
n5:category
n5:clearance
* 2.13 +/- 0.71 mL/min/kg [patients had normal renal function (CrCl > 80 mL/min] * 68 +/- 8 mL/min/kg [CrCl was 50-80 mL/min] * 34 +/- 9 mL/min/kg [CrCl was 25-49 mL/min] * 20 +/- 4 mL/min/kg [CrCl was 10 - 24 mL/min]
n5:containedIn
n8:271B3F70-363D-11E5-9242-09173F13E4C5 n8:271B3F71-363D-11E5-9242-09173F13E4C5 n8:271B3F6F-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B3F88-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B3F8A-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B3F8B-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B3F8D-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B3F87-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B3F86-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B3F89-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B3F78-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B3F85-363D-11E5-9242-09173F13E4C5